Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan 11;39(1):25-27.
doi: 10.1016/j.ccell.2020.12.017.

Lorlatinib in ALK-Rearranged Lung Cancer

Shelley Kuang  1 , Natasha B Leighl  2
Affiliations
Free article
Comment

Lorlatinib in ALK-Rearranged Lung Cancer

Shelley Kuang et al. Cancer Cell. .
Free article

Abstract

Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests N.B.L. has received institutional research funding from Pfizer, Takeda, Roche, and Novartis (in 2015) and travel support from Takeda (in 2020).

Comment on

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.

Publication types

LinkOut - more resources